Form 4: Thermo Fisher Officer Gains Shares, Options

Thermo Fisher Scientific's VP & Chief Accounting Officer, Joseph R. Holmes, reported the acquisition of common stock and stock options, alongside an adjustment to a previous performance-based award.

Summary

• Joseph R. Holmes, VP & Chief Accounting Officer, acquired 433 shares of common stock on February 25, 2026, as a performance-based restricted stock unit (RSU) award.
• The Compensation Committee determined on February 25, 2026, that performance criteria for this 433-share RSU award were satisfied.
• These 433 shares will vest in three tranches: one-third on February 28, 2026, one-third on February 28, 2027, and the final one-third on February 28, 2028, with the last tranche subject to adjustment based on long-term performance (Total Shareholder Return CAGR vs. peer group).
• Holmes also acquired 337 shares of common stock on February 25, 2026, bringing his total direct beneficial ownership to 3,082.9815 shares.
• A previous performance-based restricted stock unit award, granted on February 22, 2023, experienced a 15% reduction (6 fewer shares) on February 25, 2026, due to the company's relative TSR performance over a three-year measurement period.
• Holmes acquired 985 stock options on February 25, 2026, with an exercise price of $513.68 and an expiration date of February 25, 2036.
• These 985 stock options will vest in four equal annual installments beginning on February 28, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. While new equity awards were granted, the reduction in a prior performance-based award due to underperformance in relative TSR introduces a slight negative sentiment regarding past performance.

Positives

• Grant of 433 performance-based restricted stock units indicates satisfaction of performance criteria for that award.
• Grant of 985 stock options provides future equity upside potential for the officer.
• Increased direct beneficial ownership of common stock to 3,082.9815 shares.

Negatives

• A 15% reduction (6 fewer shares) in a previous performance-based RSU award due to the company's relative Total Shareholder Return (TSR) performance falling short of targets over a three-year measurement period.

Risks

• Future adjustment (positive or negative) to the final tranche of the 433-share RSU award based on the company's Total Shareholder Return (TSR) compound annual growth rate compared to a peer group over the measurement period from January 1, 2025, to December 31, 2027.

Future Outlook

The final tranche of the 433-share restricted stock unit award, vesting on February 28, 2028, is subject to adjustment based on Thermo Fisher Scientific's Total Shareholder Return (TSR) compound annual growth rate compared to a peer group over the period from January 1, 2025, to December 31, 2027.

Management Comments

• The Company's Compensation Committee determined on February 25, 2026, that the performance criteria related to the 433-share restricted stock unit award were satisfied.
• On February 25, 2026, the Compensation Committee certified a 15% reduction in a previous performance-based restricted stock unit award based on the Company's relative TSR performance over the three-year measurement period.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through performance-based equity awards, is a standard practice across the life sciences and diagnostics industry. The structure of these awards, linking vesting to TSR performance against a peer group, aligns executive incentives with shareholder value creation, a common trend in corporate governance.

Comparison to Industry Standards

• Performance-based restricted stock units (RSUs) and stock options are standard components of executive compensation packages in large, publicly traded companies, including those in the life sciences sector like Thermo Fisher Scientific.
• Tying a portion of executive equity awards to relative Total Shareholder Return (TSR) performance against a peer group is a widely adopted best practice in corporate governance, aiming to align executive incentives with long-term shareholder value creation. Companies such as Danaher Corporation and Abbott Laboratories often employ similar performance metrics for their executive compensation.
• The vesting schedule for the RSUs (three annual tranches) and stock options (four annual installments) is typical for long-term incentive plans designed to retain key executives.

Stakeholder Impact

• Shareholders: The grant of performance-based equity awards aligns executive incentives with shareholder value, but the reduction in a prior award due to relative TSR underperformance could be viewed negatively regarding past executive performance.

Next Steps

• One-third of the 433-share RSU award will vest on February 28, 2026.
• One-third of the 433-share RSU award will vest on February 28, 2027.
• The remaining one-third of the 433-share RSU award will vest on February 28, 2028, subject to long-term performance adjustment.
• The 985 stock options will vest in four equal annual installments beginning on February 28, 2027.

Key Dates

Recommendation

The filing details routine executive compensation events, including new equity grants and an adjustment to a prior performance award. While the reduction in a previous award due to relative TSR underperformance is a minor negative, the overall activity does not suggest a fundamental shift in the company's outlook or a strong buy/sell signal. Investors should hold and monitor broader company performance and market trends.

Keywords

Thermo Fisher Scientific, TMO, Joseph R. Holmes, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Performance-Based Awards, Beneficial Ownership